{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2024,12,12]],"date-time":"2024-12-12T05:50:54Z","timestamp":1733982654428,"version":"3.30.2"},"reference-count":75,"publisher":"American Society of Hematology","issue":"1","content-domain":{"domain":["ashpublications.org"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2024,12,6]]},"abstract":"<jats:title>Abstract<\/jats:title>\n               <jats:p>The last 20 years witnessed relevant clinical advancements in the field of hematopoietic cell transplantation (HCT) for leukemia patients. The introduction of novel conditioning regimens, a better prophylaxis and management of graft- versus-host disease, and an ameliorated posttransplant support system improved safety and, therefore, outcomes. On the other hand, leukemia relapse remains the major cause of allogeneic HCT failure. Efforts have been made to understand the mechanisms of leukemia relapse, and new insights that clarify how donor immunity exerts graft-versus- leukemia (GVL) activity are available. Such studies set the base to design novel transplant strategies that can improve disease control. In our review we begin by discussing the most relevant criteria to choose a donor that provides a strong GVL effect. We also report some of the novel conditioning regimens that aim to deliver and extend myeloablation in order to reduce the disease burden at time of graft infusion. Finally, we discuss how the graft can be manipulated to limit the use of immune suppression and ensure potent antileukemic activity.<\/jats:p>","DOI":"10.1182\/hematology.2024000590","type":"journal-article","created":{"date-parts":[[2024,12,6]],"date-time":"2024-12-06T15:05:49Z","timestamp":1733497549000},"page":"627-634","update-policy":"https:\/\/doi.org\/10.1182\/blood.2019cm0000","source":"Crossref","is-referenced-by-count":0,"title":["Novel conditioning and prophylaxis regimens for relapse prevention"],"prefix":"10.1182","volume":"2024","author":[{"given":"Antonella","family":"Mancusi","sequence":"first","affiliation":[{"name":"1 Division of Hematology, Department of Medicine and Surgery, University of Perugia, Italy"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Loredana","family":"Ruggeri","sequence":"additional","affiliation":[{"name":"2 Hematology Section, Perugia University Hospital, Perugia, Italy"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Antonio","family":"Pierini","sequence":"additional","affiliation":[{"name":"1 Division of Hematology, Department of Medicine and Surgery, University of Perugia, Italy"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"234","published-online":{"date-parts":[[2024,12,6]]},"reference":[{"issue":"1","key":"2024121115464675300_hem2024000590C1","doi-asserted-by":"crossref","first-page":"333","DOI":"10.1182\/blood.V94.1.333.413a31_333_339","article-title":"Role of natural killer cell alloreactivity in HLA-mismatched hematopoietic stem cell transplantation","volume":"94","author":"Ruggeri","year":"1999","journal-title":"Blood"},{"issue":"5562","key":"2024121115464675300_hem2024000590C2","doi-asserted-by":"crossref","first-page":"2097","DOI":"10.1126\/science.1068440","article-title":"Effectiveness of donor natural killer cell alloreactivity in mismatched hematopoietic transplants","volume":"295","author":"Ruggeri","year":"2002","journal-title":"Science"},{"issue":"2","key":"2024121115464675300_hem2024000590C3","doi-asserted-by":"crossref","first-page":"83","DOI":"10.1016\/0165-2478(94)90176-7","article-title":"Ontogeny, specific functions and receptors of human natural killer cells","volume":"40","author":"Moretta","year":"1994","journal-title":"Immunol Lett"},{"issue":"13","key":"2024121115464675300_hem2024000590C4","doi-asserted-by":"crossref","first-page":"3119","DOI":"10.1182\/blood-2008-06-164103","article-title":"Anti-leukemia activity of alloreactive NK cells in KIR ligand-mismatched haploidentical HSCT for pediatric patients: evaluation of the functional role of activating KIR and redefinition of inhibitory KIR specificity","volume":"113","author":"Pende","year":"2009","journal-title":"Blood"},{"issue":"1","key":"2024121115464675300_hem2024000590C5","doi-asserted-by":"crossref","first-page":"433","DOI":"10.1182\/blood-2006-07-038687","article-title":"Donor natural killer cell allorecognition of missing self in haploidentical hematopoietic transplantation for acute myeloid leukemia: challenging its predictive value","volume":"110","author":"Ruggeri","year":"2007","journal-title":"Blood"},{"issue":"10","key":"2024121115464675300_hem2024000590C6","doi-asserted-by":"crossref","first-page":"3825","DOI":"10.1182\/blood-2002-04-1197","article-title":"Evaluation of KIR ligand incompatibility in mismatched unrelated donor hematopoietic transplants","volume":"100","author":"Davies","year":"2002","journal-title":"Blood"},{"issue":"3","key":"2024121115464675300_hem2024000590C7","doi-asserted-by":"crossref","first-page":"814","DOI":"10.1182\/blood-2003-01-0091","article-title":"Survival advantage with KIR ligand incompatibility in hematopoietic stem cell transplantation from unrelated donors","volume":"102","author":"Giebel","year":"2003","journal-title":"Blood"},{"issue":"2","key":"2024121115464675300_hem2024000590C8","doi-asserted-by":"crossref","first-page":"247","DOI":"10.1182\/blood-2017-05-780668","article-title":"NK cell recovery after haploidentical HSCT with posttransplant cyclophosphamide: dynamics and clinical implications","volume":"131","author":"Russo","year":"2018","journal-title":"Blood"},{"issue":"7","key":"2024121115464675300_hem2024000590C9","doi-asserted-by":"crossref","first-page":"2990","DOI":"10.1182\/blood-2008-01-135285","article-title":"Survival after T cell-depleted haploidentical stem cell transplantation is improved using the mother as donor","volume":"112","author":"Stern","year":"2008","journal-title":"Blood"},{"issue":"1","key":"2024121115464675300_hem2024000590C10","doi-asserted-by":"crossref","first-page":"41","DOI":"10.1172\/JCI6611","article-title":"Microchimerism of maternal origin persists into adult life","volume":"104","author":"Maloney","year":"1999","journal-title":"J Clin Invest"},{"issue":"4625","key":"2024121115464675300_hem2024000590C11","doi-asserted-by":"crossref","first-page":"1735","DOI":"10.1038\/1811735a0","article-title":"Leucocyte antibodies in sera from pregnant women","volume":"181","author":"Van Rood","year":"1958","journal-title":"Nature"},{"issue":"6","key":"2024121115464675300_hem2024000590C12","doi-asserted-by":"crossref","first-page":"1210","DOI":"10.1016\/j.bbmt.2019.01.030","article-title":"Comparable outcomes after hematopoietic stem cell transplantation from mother donors and matched unrelated donors in patients with hematopoietic malignancies","volume":"25","author":"Ma","year":"2019","journal-title":"Biol Blood Marrow Transplant"},{"issue":"4","key":"2024121115464675300_hem2024000590C13","doi-asserted-by":"crossref","first-page":"206.e1","DOI":"10.1016\/j.jtct.2022.01.001","article-title":"Mother donors improve outcomes after HLA haploidentical transplantation: a study by the Cellular Therapy and Immunobiology Working Party of the European Society for Blood and Marrow Transplantation","volume":"28","author":"Ruggeri","year":"2022","journal-title":"Transplant Cell Ther"},{"issue":"6","key":"2024121115464675300_hem2024000590C14","doi-asserted-by":"crossref","first-page":"843","DOI":"10.1182\/blood-2014-03-563130","article-title":"Who is the best donor for a related HLA haplotype-mismatched transplant?","volume":"124","author":"Wang","year":"2014","journal-title":"Blood"},{"issue":"4","key":"2024121115464675300_hem2024000590C15","doi-asserted-by":"crossref","first-page":"366","DOI":"10.1016\/S1470-2045(12)70004-9","article-title":"Effect of T-cell-epitope matching at HLA-DPB1 in recipients of unrelated-donor haemopoietic-cell transplantation: a retrospective study","volume":"13","author":"Fleischhauer","year":"2012","journal-title":"Lancet Oncol"},{"issue":"1","key":"2024121115464675300_hem2024000590C16","doi-asserted-by":"crossref","first-page":"532","DOI":"10.1182\/hematology.2019000057","article-title":"Selection of matched unrelated donors moving forward: from HLA allele counting to functional matching","volume":"2019","author":"Fleischhauer","year":"2019","journal-title":"Hematology Am Soc Hematol Educ Program"},{"issue":"3","key":"2024121115464675300_hem2024000590C17","doi-asserted-by":"crossref","first-page":"726","DOI":"10.1182\/blood-2008-07-171926","article-title":"Donors with group B KIR haplotypes improve relapse-free survival after unrelated hematopoietic cell transplantation for acute myelogenous leukemia","volume":"113","author":"Cooley","year":"2009","journal-title":"Blood"},{"key":"2024121115464675300_hem2024000590C18","doi-asserted-by":"crossref","first-page":"1350470","DOI":"10.3389\/fimmu.2024.1350470","article-title":"Donor KIR genotype based outcome prediction after allogeneic stem cell transplantation: no land in sight","volume":"15","author":"Schetelig","year":"2024","journal-title":"Front Immunol"},{"issue":"10","key":"2024121115464675300_hem2024000590C19","doi-asserted-by":"crossref","first-page":"944","DOI":"10.1056\/NEJMoa1602074","article-title":"Cord-blood transplantation in patients with minimal residual disease","volume":"375","author":"Milano","year":"2016","journal-title":"N Engl J Med"},{"issue":"20","key":"2024121115464675300_hem2024000590C20","doi-asserted-by":"crossref","first-page":"4064","DOI":"10.1182\/bloodadvances.2021004462","article-title":"Comparison of haploidentical and umbilical cord blood transplantation after myeloablative conditioning","volume":"5","author":"Wagner","year":"2021","journal-title":"Blood Adv"},{"issue":"10","key":"2024121115464675300_hem2024000590C21","doi-asserted-by":"crossref","first-page":"710.e1","DOI":"10.1016\/j.jtct.2022.07.006","article-title":"Comparison of outcomes after unrelated double-unit cord blood and haploidentical peripheral blood stem cell transplantation in adults with acute myelogenous leukemia: a study on behalf of Eurocord and the Acute Leukemia Working Party of the European Society for Blood and Marrow Transplantation","volume":"28","author":"Ruggeri","year":"2022","journal-title":"Transplant Cell Ther"},{"issue":"11","key":"2024121115464675300_hem2024000590C22","doi-asserted-by":"crossref","first-page":"1504","DOI":"10.1038\/bmt.2017.83","article-title":"Conditioning regimens for allogeneic hematopoietic stem cell transplants in acute myeloid leukemia","volume":"52","author":"Jethava","year":"2017","journal-title":"Bone Marrow Transplant"},{"issue":"11","key":"2024121115464675300_hem2024000590C23","doi-asserted-by":"crossref","first-page":"1154","DOI":"10.1200\/JCO.2016.70.7091","article-title":"Myeloablative versus reduced-intensity hematopoietic cell transplantation for acute myeloid leukemia and myelodysplastic syndromes","volume":"35","author":"Scott","year":"2017","journal-title":"J Clin Oncol"},{"issue":"6","key":"2024121115464675300_hem2024000590C24","doi-asserted-by":"crossref","first-page":"483.e1","DOI":"10.1016\/j.jtct.2021.02.031","article-title":"Myeloablative versus reduced-intensity conditioning for hematopoietic cell transplantation in acute myelogenous leukemia and myelodysplastic syndromes \u2013 long-term follow-up of the BMT CTN 0901 clinical trial","volume":"27","author":"Scott","year":"2021","journal-title":"Transplant Cell Ther"},{"issue":"19","key":"2024121115464675300_hem2024000590C25","doi-asserted-by":"crossref","first-page":"2836","DOI":"10.1182\/bloodadvances.2019000627","article-title":"Myeloablative vs reduced intensity T-cell-replete haploidentical transplantation for hematologic malignancy","volume":"3","author":"Solomon","year":"2019","journal-title":"Blood Adv"},{"issue":"35","key":"2024121115464675300_hem2024000590C26","doi-asserted-by":"crossref","first-page":"4167","DOI":"10.1200\/JCO.2015.62.7273","article-title":"Phase II study of allogeneic transplantation for older patients with acute myeloid leukemia in first complete remission using a reduced-intensity conditioning regimen: results from cancer and leukemia group B 100103 (Alliance for Clinical Trials in Oncology)\/blood and marrow transplant clinical trial network 0502","volume":"33","author":"Devine","year":"2015","journal-title":"J Clin Oncol"},{"issue":"12","key":"2024121115464675300_hem2024000590C27","doi-asserted-by":"crossref","first-page":"1273","DOI":"10.1200\/JCO.19.03011","article-title":"Impact of conditioning intensity of allogeneic transplantation for acute myeloid leukemia with genomic evidence of residual disease","volume":"38","author":"Hourigan","year":"2020","journal-title":"J Clin Oncol"},{"issue":"1","key":"2024121115464675300_hem2024000590C28","doi-asserted-by":"crossref","first-page":"137","DOI":"10.1038\/leu.2014.173","article-title":"Comparison of minimal residual disease as outcome predictor for AML patients in first complete remission undergoing myeloablative or nonmyeloablative allogeneic hematopoietic cell transplantation","volume":"29","author":"Walter","year":"2015","journal-title":"Leukemia"},{"issue":"7","key":"2024121115464675300_hem2024000590C29","doi-asserted-by":"crossref","first-page":"1227","DOI":"10.1016\/j.bbmt.2016.03.029","article-title":"Minimal identifiable disease and the role of conditioning intensity in hematopoietic cell transplantation for myelodysplastic syndrome and acute myelogenous leukemia evolving from myelodysplastic syndrome","volume":"22","author":"Festuccia","year":"2016","journal-title":"Biol Blood Marrow Transplant"},{"issue":"3","key":"2024121115464675300_hem2024000590C30","doi-asserted-by":"crossref","first-page":"3379","DOI":"10.18632\/oncotarget.23273","article-title":"Thiotepa-busulfan-fludarabine compared to busulfan-fludarabine for sibling and unrelated donor transplant in acute myeloid leukemia in first remission","volume":"9","author":"Saraceni","year":"2018","journal-title":"Oncotarget"},{"issue":"4","key":"2024121115464675300_hem2024000590C31","doi-asserted-by":"crossref","first-page":"698","DOI":"10.1016\/j.bbmt.2019.12.725","article-title":"Allogeneic hemopoietic stem cell transplants in patients with acute myeloid leukemia (AML) prepared with busulfan and fludarabine (BUFLU) or thiotepa, busulfan, and fludarabine (TBF): a retrospective study","volume":"26","author":"Sora","year":"2020","journal-title":"Biol Blood Marrow Transplant"},{"issue":"3","key":"2024121115464675300_hem2024000590C32","doi-asserted-by":"crossref","first-page":"622","DOI":"10.1038\/s41409-020-01074-z","article-title":"Comparable outcomes of haploidentical transplant with TBF conditioning versus matched unrelated donor with fludarabine\/busulfan conditioning for acute myeloid leukemia","volume":"56","author":"Bazarbachi","year":"2021","journal-title":"Bone Marrow Transplant"},{"issue":"4","key":"2024121115464675300_hem2024000590C33","doi-asserted-by":"crossref","first-page":"339","DOI":"10.1038\/sj.bmt.1705259","article-title":"Reduced-toxicity conditioning with treosulfan, fludarabine and ATG as preparative regimen for allogeneic stem cell transplantation (alloSCT) in elderly patients with secondary acute myeloid leukemia (sAML) or myelodysplastic syndrome (MDS)","volume":"37","author":"Kr\u00f6ger","year":"2006","journal-title":"Bone Marrow Transplant"},{"issue":"12","key":"2024121115464675300_hem2024000590C34","doi-asserted-by":"crossref","first-page":"2352","DOI":"10.1080\/10428190701671051","article-title":"Fludarabine and treosulfan: a novel modified myeloablative regimen for allogeneic hematopoietic stem-cell transplantation with effective antileukemia activity in patients with acute myeloid leukemia and myelodysplastic syndromes","volume":"48","author":"Shimoni","year":"2007","journal-title":"Leuk Lymphoma"},{"issue":"9","key":"2024121115464675300_hem2024000590C35","doi-asserted-by":"crossref","first-page":"1171","DOI":"10.1038\/bmt.2011.242","article-title":"Allogeneic hematopoietic SCT in patients with AML following treosulfan\/fludarabine conditioning","volume":"47","author":"Casper","year":"2012","journal-title":"Bone Marrow Transplant"},{"issue":"9","key":"2024121115464675300_hem2024000590C36","doi-asserted-by":"crossref","first-page":"1344","DOI":"10.3324\/haematol.2011.043810","article-title":"Reduced-toxicity conditioning with treosulfan and fludarabine in allogeneic hematopoietic stem cell transplantation for myelodysplastic syndromes: final results of an international prospective phase II trial","volume":"96","author":"Ruutu","year":"2011","journal-title":"Haematologica"},{"issue":"14","key":"2024121115464675300_hem2024000590C37","doi-asserted-by":"crossref","first-page":"2671","DOI":"10.1002\/cncr.30646","article-title":"Long-term outcome after a treosulfan- based conditioning regimen for patients with acute myeloid leukemia: a report from the Acute Leukemia Working Party of the European Society for Blood and Marrow Transplantation","volume":"123","author":"Nagler","year":"2017","journal-title":"Cancer"},{"issue":"1","key":"2024121115464675300_hem2024000590C38","doi-asserted-by":"crossref","first-page":"e28","DOI":"10.1016\/S2352-3026(19)30157-7","article-title":"Treosulfan or busulfan plus fludarabine as conditioning treatment before allogeneic haemopoietic stem cell transplantation for older patients with acute myeloid leukaemia or myelodysplastic syndrome (MC-FludT.14\/L): a randomised, non-inferiority, phase 3 trial","volume":"7","author":"Beelen","year":"2020","journal-title":"Lancet Haematol"},{"issue":"8","key":"2024121115464675300_hem2024000590C39","doi-asserted-by":"crossref","first-page":"1023","DOI":"10.1002\/ajh.26620","article-title":"Treosulfan compared with reduced-intensity busulfan improves allogeneic hematopoietic cell transplantation outcomes of older acute myeloid leukemia and myelodysplastic syndrome patients: final analysis of a prospective randomized trial","volume":"97","author":"Beelen","year":"2022","journal-title":"Am J Hematol"},{"issue":"24","key":"2024121115464675300_hem2024000590C40","doi-asserted-by":"crossref","first-page":"3871","DOI":"10.1182\/blood-2013-08-519009","article-title":"Prospective cohort study comparing intravenous busulfan to total body irradiation in hematopoietic cell transplantation","volume":"122","author":"Bredeson","year":"2013","journal-title":"Blood"},{"issue":"13","key":"2024121115464675300_hem2024000590C41","doi-asserted-by":"crossref","first-page":"3569","DOI":"10.1182\/blood.V98.13.3569","article-title":"Busulfan plus cyclophosphamide compared with total-body irradiation plus cyclophosphamide before marrow transplantation for myeloid leukemia: long-term follow-up of 4 randomized studies","volume":"98","author":"Soci\u00e9","year":"2001","journal-title":"Blood"},{"issue":"28","key":"2024121115464675300_hem2024000590C42","doi-asserted-by":"crossref","first-page":"3549","DOI":"10.1200\/JCO.2013.48.8114","article-title":"Allogeneic hematopoietic stem-cell transplantation for acute myeloid leukemia in remission: comparison of intravenous busulfan plus cyclophosphamide (Cy) vs total-body irradiation plus Cy as conditioning regimen\u2014a report from the acute leukemia working party of the European group for blood and marrow transplantation","volume":"31","author":"Nagler","year":"2013","journal-title":"J Clin Oncol"},{"issue":"4","key":"2024121115464675300_hem2024000590C43","doi-asserted-by":"crossref","first-page":"1115","DOI":"10.1046\/j.1365-2141.2002.03973.x","article-title":"Comparison of outcome following allogeneic bone marrow transplantation with cyclophosphamide-total body irradiation versus busulphan-cyclophosphamide conditioning regimens for acute myelogenous leukaemia in first remission","volume":"119","author":"Litzow","year":"2002","journal-title":"Br J Haematol"},{"issue":"9","key":"2024121115464675300_hem2024000590C44","doi-asserted-by":"crossref","first-page":"1867","DOI":"10.1182\/blood.V76.9.1867.1867","article-title":"Allogeneic marrow transplantation in patients with acute myeloid leukemia in first remission: a randomized trial of two irradiation regimens","volume":"76","author":"Clift","year":"1990","journal-title":"Blood"},{"issue":"4","key":"2024121115464675300_hem2024000590C45","doi-asserted-by":"crossref","first-page":"1455","DOI":"10.1182\/blood.V92.4.1455","article-title":"Long-term follow-up of a randomized trial of two irradiation regimens for patients receiving allogeneic marrow transplants during first remission of acute myeloid leukemia","volume":"92","author":"Clift","year":"1998","journal-title":"Blood"},{"issue":"4","key":"2024121115464675300_hem2024000590C46","doi-asserted-by":"crossref","first-page":"295","DOI":"10.1200\/JCO.20.02529","article-title":"Total body irradiation or chemotherapy conditioning in childhood ALL: a multinational, randomized, noninferiority phase III study","volume":"39","author":"Peters","year":"2021","journal-title":"J Clin Oncol"},{"issue":"3","key":"2024121115464675300_hem2024000590C47","doi-asserted-by":"crossref","first-page":"306","DOI":"10.1016\/j.bbmt.2005.10.026","article-title":"Targeted total marrow irradiation using three-dimensional image-guided tomographic intensity-modulated radiation therapy: an alternative to standard total body irradiation","volume":"12","author":"Wong","year":"2006","journal-title":"Biol Blood Marrow Transplant"},{"issue":"1","key":"2024121115464675300_hem2024000590C48","doi-asserted-by":"crossref","first-page":"309","DOI":"10.1182\/blood-2010-06-288357","article-title":"Phase 1\/2 trial of total marrow and lymph node irradiation to augment reduced-intensity transplantation for advanced hematologic malignancies","volume":"117","author":"Rosenthal","year":"2011","journal-title":"Blood"},{"issue":"2","key":"2024121115464675300_hem2024000590C49","doi-asserted-by":"crossref","first-page":"301","DOI":"10.1016\/j.bbmt.2017.09.019","article-title":"Total marrow lymphoid irradiation\/fludarabine\/melphalan conditioning for allogeneic hematopoietic cell transplantation","volume":"24","author":"Jensen","year":"2018","journal-title":"Biol Blood Marrow Transplant"},{"issue":"7","key":"2024121115464675300_hem2024000590C50","doi-asserted-by":"crossref","first-page":"368.e1","DOI":"10.1016\/j.jtct.2022.03.025","article-title":"Total marrow and lymphoid irradiation with posttransplantation cyclophosphamide for patients with AML in remission","volume":"28","author":"Stein","year":"2022","journal-title":"Transplant Cell Ther"},{"issue":"14","key":"2024121115464675300_hem2024000590C51","doi-asserted-by":"crossref","first-page":"4098","DOI":"10.1182\/bloodadvances.2022007264","article-title":"Total marrow and lymphoid irradiation as conditioning in haploidentical transplant with posttransplant cyclophosphamide","volume":"6","author":"Al Malki","year":"2022","journal-title":"Blood Adv"},{"issue":"7","key":"2024121115464675300_hem2024000590C52","doi-asserted-by":"crossref","first-page":"1048","DOI":"10.1002\/cncr.29163","article-title":"Reduced-intensity conditioning with fludarabine and busulfan versus fludarabine and melphalan for patients with acute myeloid leukemia: a report from the Acute Leukemia Working Party of the European Group for Blood and Marrow Transplantation","volume":"121","author":"Baron","year":"2015","journal-title":"Cancer"},{"issue":"10","key":"2024121115464675300_hem2024000590C53","doi-asserted-by":"crossref","first-page":"1019.e1","DOI":"10.1016\/j.jtct.2024.07.024","article-title":"Lower weight-based mycophenolate mofetil dosing is associated with superior outcomes after haploidentical hematopoietic cell transplant with posttransplant cyclophosphamide","volume":"30","author":"Elmariah","year":"2024","journal-title":"Transplant Cell Ther"},{"issue":"17","key":"2024121115464675300_hem2024000590C54","doi-asserted-by":"crossref","first-page":"1186","DOI":"10.1056\/NEJM199810223391702","article-title":"Treatment of high-risk acute leukemia with T-cell-depleted stem cells from related donors with one fully mismatched HLA haplotype","volume":"339","author":"Aversa","year":"1998","journal-title":"N Engl J Med"},{"issue":"15","key":"2024121115464675300_hem2024000590C55","doi-asserted-by":"crossref","first-page":"3447","DOI":"10.1200\/JCO.2005.09.117","article-title":"Full haplotype-mismatched hematopoietic stem-cell transplantation: a phase II study in patients with acute leukemia at high risk of relapse","volume":"23","author":"Aversa","year":"2005","journal-title":"J Clin Oncol"},{"issue":"suppl 2","key":"2024121115464675300_hem2024000590C56","doi-asserted-by":"crossref","first-page":"S6","DOI":"10.1038\/bmt.2015.87","article-title":"Improved immune recovery after transplantation of TCR\u03b1\u03b2\/CD19-depleted allografts from haploidentical donors in pediatric patients","volume":"50","author":"Lang","year":"2015","journal-title":"Bone Marrow Transplant"},{"issue":"5","key":"2024121115464675300_hem2024000590C57","doi-asserted-by":"crossref","first-page":"677","DOI":"10.1182\/blood-2017-04-779769","article-title":"Outcome of children with acute leukemia given HLA-haploidentical HSCT after \u03b1\u03b2 T-cell and B-cell depletion","volume":"130","author":"Locatelli","year":"2017","journal-title":"Blood"},{"issue":"24","key":"2024121115464675300_hem2024000590C58","doi-asserted-by":"crossref","first-page":"2594","DOI":"10.1182\/blood-2018-07-861575","article-title":"Unrelated donor vs HLA-haploidentical \u03b1\/\u03b2 T-cell- and B-cell-depleted HSCT in children with acute leukemia","volume":"132","author":"Bertaina","year":"2018","journal-title":"Blood"},{"issue":"7","key":"2024121115464675300_hem2024000590C59","doi-asserted-by":"crossref","first-page":"2677","DOI":"10.1172\/JCI81229","article-title":"Outcomes of acute leukemia patients transplanted with naive T cell-depleted stem cell grafts","volume":"125","author":"Bleakley","year":"2015","journal-title":"J Clin Invest"},{"key":"2024121115464675300_hem2024000590C60","doi-asserted-by":"crossref","first-page":"1009143","DOI":"10.3389\/fonc.2022.1009143","article-title":"Selective depletion of na\u00efve T cells by targeting CD45RA","volume":"12","author":"Naik","year":"2022","journal-title":"Front Oncol"},{"issue":"5","key":"2024121115464675300_hem2024000590C61","doi-asserted-by":"crossref","first-page":"489","DOI":"10.1016\/S1470-2045(09)70074-9","article-title":"Infusion of suicide-gene-engineered donor lymphocytes after family haploidentical haemopoietic stem-cell transplantation for leukaemia (the TK007 trial): a non-randomised phase I-II study","volume":"10","author":"Ciceri","year":"2009","journal-title":"Lancet Oncol"},{"issue":"9","key":"2024121115464675300_hem2024000590C62","doi-asserted-by":"crossref","first-page":"1820","DOI":"10.1182\/blood-2012-01-405670","article-title":"T-cell suicide gene therapy prompts thymic renewal in adults after hematopoietic stem cell transplantation","volume":"120","author":"Vago","year":"2012","journal-title":"Blood"},{"issue":"25","key":"2024121115464675300_hem2024000590C63","doi-asserted-by":"crossref","first-page":"3895","DOI":"10.1182\/blood-2014-01-551671","article-title":"Long-term outcome after haploidentical stem cell transplant and infusion of T cells expressing the inducible caspase 9 safety transgene","volume":"123","author":"Zhou","year":"2014","journal-title":"Blood"},{"issue":"26","key":"2024121115464675300_hem2024000590C64","doi-asserted-by":"crossref","first-page":"4103","DOI":"10.1182\/blood-2015-02-628354","article-title":"Inducible caspase-9 suicide gene controls adverse effects from alloreplete T cells after haploidentical stem cell transplantation","volume":"125","author":"Zhou","year":"2015","journal-title":"Blood"},{"issue":"14","key":"2024121115464675300_hem2024000590C65","doi-asserted-by":"crossref","first-page":"3921","DOI":"10.1182\/blood-2010-10-311894","article-title":"Tregs prevent GVHD and promote immune reconstitution in HLA-haploidentical transplantation","volume":"117","author":"Di Ianni","year":"2011","journal-title":"Blood"},{"issue":"3","key":"2024121115464675300_hem2024000590C66","doi-asserted-by":"crossref","first-page":"1061","DOI":"10.1182\/blood-2010-07-293795","article-title":"Infusion of ex vivo expanded T regulatory cells in adults transplanted with umbilical cord blood: safety profile and detection kinetics","volume":"117","author":"Brunstein","year":"2011","journal-title":"Blood"},{"issue":"4","key":"2024121115464675300_hem2024000590C67","doi-asserted-by":"crossref","first-page":"638","DOI":"10.1182\/blood-2014-03-564401","article-title":"HLA-haploidentical transplantation with regulatory and conventional T-cell adoptive immunotherapy prevents acute leukemia relapse","volume":"124","author":"Martelli","year":"2014","journal-title":"Blood"},{"issue":"5","key":"2024121115464675300_hem2024000590C68","doi-asserted-by":"crossref","first-page":"1199","DOI":"10.1182\/bloodadvances.2020003739","article-title":"Haploidentical age-adapted myeloablative transplant and regulatory and effector T cells for acute myeloid leukemia","volume":"5","author":"Pierini","year":"2021","journal-title":"Blood Adv"},{"issue":"10","key":"2024121115464675300_hem2024000590C69","doi-asserted-by":"crossref","first-page":"e127244","DOI":"10.1172\/jci.insight.127244","article-title":"Transplantation of donor grafts with defined ratio of conventional and regulatory T cells in HLA-matched recipients","volume":"4","author":"Meyer","year":"2019","journal-title":"JCI Insight"},{"issue":"5","key":"2024121115464675300_hem2024000590C70","doi-asserted-by":"crossref","first-page":"1105","DOI":"10.1182\/bloodadvances.2023011625","article-title":"Single-center randomized trial of T-reg graft alone vs T-reg graft plus tacrolimus for the prevention of acute GVHD","volume":"8","author":"Bader","year":"2024","journal-title":"Blood Adv"},{"issue":"23","key":"2024121115464675300_hem2024000590C71","doi-asserted-by":"crossref","first-page":"3664","DOI":"10.1182\/blood-2014-01-552984","article-title":"Validation and refinement of the disease risk index for allogeneic stem cell transplantation","volume":"123","author":"Armand","year":"2014","journal-title":"Blood"},{"issue":"4","key":"2024121115464675300_hem2024000590C72","doi-asserted-by":"crossref","first-page":"603","DOI":"10.1038\/s41591-019-0400-z","article-title":"Immune signature drives leukemia escape and relapse after hematopoietic cell transplantation","volume":"25","author":"Toffalori","year":"2019","journal-title":"Nat Med"},{"issue":"1","key":"2024121115464675300_hem2024000590C73","doi-asserted-by":"crossref","first-page":"12","DOI":"10.1038\/s41409-019-0499-z","article-title":"The European Society for Blood and Marrow Transplantation (EBMT) consensus recommendations for donor selection in haploidentical hematopoietic cell transplantation","volume":"55","author":"Ciurea","year":"2020","journal-title":"Bone Marrow Transplant"},{"issue":"4","key":"2024121115464675300_hem2024000590C74","doi-asserted-by":"crossref","first-page":"533","DOI":"10.1016\/j.bbmt.2009.11.022","article-title":"Improved survival with inhibitory killer immunoglobulin receptor (KIR) gene mismatches and KIR haplotype B donors after nonmyeloablative, HLA- haploidentical bone marrow transplantation","volume":"16","author":"Symons","year":"2010","journal-title":"Biol Blood Marrow Transplant"},{"issue":"8","key":"2024121115464675300_hem2024000590C75","doi-asserted-by":"crossref","first-page":"1044","DOI":"10.1182\/blood-2015-06-653667","article-title":"Umbilical cord blood-derived T regulatory cells to prevent GVHD: kinetics, toxicity profile, and clinical effect","volume":"127","author":"Brunstein","year":"2016","journal-title":"Blood"}],"container-title":["Hematology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/ashpublications.org\/hematology\/article-pdf\/2024\/1\/627\/2346402\/627mancusi.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/ashpublications.org\/hematology\/article-pdf\/2024\/1\/627\/2346402\/627mancusi.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,12,11]],"date-time":"2024-12-11T20:13:30Z","timestamp":1733948010000},"score":1,"resource":{"primary":{"URL":"https:\/\/ashpublications.org\/hematology\/article\/2024\/1\/627\/526194\/Novel-conditioning-and-prophylaxis-regimens-for"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,12,6]]},"references-count":75,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2024,12,6]]},"published-print":{"date-parts":[[2024,12,6]]}},"URL":"https:\/\/doi.org\/10.1182\/hematology.2024000590","relation":{},"ISSN":["1520-4391","1520-4383"],"issn-type":[{"type":"print","value":"1520-4391"},{"type":"electronic","value":"1520-4383"}],"subject":[],"published-other":{"date-parts":[[2024,12,6]]},"published":{"date-parts":[[2024,12,6]]}}}